Immunocore (NASDAQ:IMCR) Raised to Strong-Buy at Zacks Research

Immunocore (NASDAQ:IMCR) was upgraded by Zacks Research from a “strong sell” rating to a “strong-buy” rating in a report issued on Thursday,Zacks.com reports.

Other research analysts have also recently issued research reports about the company. Needham & Company LLC upped their target price on Immunocore from $71.00 to $75.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Jefferies Financial Group cut Immunocore from a “buy” rating to a “hold” rating and dropped their price objective for the company from $48.00 to $33.00 in a report on Monday, March 16th. Wall Street Zen raised Immunocore from a “hold” rating to a “buy” rating in a research report on Saturday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Immunocore in a research note on Tuesday, April 21st. Finally, UBS Group set a $55.00 target price on shares of Immunocore and gave the company a “buy” rating in a research note on Wednesday, January 7th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Immunocore presently has a consensus rating of “Moderate Buy” and an average target price of $57.75.

Immunocore Price Performance

Immunocore stock opened at $29.58 on Thursday. Immunocore has a 12-month low of $27.44 and a 12-month high of $40.71. The company has a current ratio of 4.18, a quick ratio of 4.01 and a debt-to-equity ratio of 1.00. The firm has a 50-day moving average price of $30.87 and a 200-day moving average price of $33.32. The firm has a market capitalization of $1.50 billion, a PE ratio of -53.78 and a beta of 0.74.

Immunocore (NASDAQ:IMCR) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.25 EPS for the quarter, beating the consensus estimate of ($0.26) by $0.51. Immunocore had a negative net margin of 6.68% and a negative return on equity of 7.07%. The company had revenue of $106.68 million for the quarter, compared to the consensus estimate of $145.15 million. During the same period in the prior year, the firm posted $0.10 EPS. The firm’s revenue was up 13.6% compared to the same quarter last year. As a group, equities research analysts forecast that Immunocore will post -0.83 EPS for the current year.

Insider Activity at Immunocore

In other Immunocore news, CEO Bahija Jallal sold 11,474 shares of the firm’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $32.35, for a total transaction of $371,183.90. Following the transaction, the chief executive officer owned 12,343 shares of the company’s stock, valued at approximately $399,296.05. This trade represents a 48.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Leger Tina Amber St sold 1,000 shares of the business’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $32.35, for a total transaction of $32,350.00. Following the completion of the sale, the insider owned 1,119 shares of the company’s stock, valued at approximately $36,199.65. This represents a 47.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 19,137 shares of company stock worth $619,082 over the last three months. 10.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Immunocore

Institutional investors have recently bought and sold shares of the business. Leonteq Securities AG bought a new position in Immunocore in the fourth quarter worth approximately $30,000. Harbour Investments Inc. lifted its holdings in Immunocore by 60.2% during the fourth quarter. Harbour Investments Inc. now owns 1,033 shares of the company’s stock worth $36,000 after buying an additional 388 shares during the period. Rockefeller Capital Management L.P. bought a new stake in Immunocore during the 4th quarter valued at $47,000. Arax Advisory Partners boosted its position in Immunocore by 302.9% during the 4th quarter. Arax Advisory Partners now owns 1,386 shares of the company’s stock valued at $48,000 after acquiring an additional 1,042 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Immunocore by 37.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,120 shares of the company’s stock valued at $74,000 after acquiring an additional 572 shares during the period. 84.50% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Immunocore

Here are the key news stories impacting Immunocore this week:

• Positive Sentiment: HC Wainwright raised several forward earnings estimates for Immunocore, including FY2027 to $0.90 EPS, FY2028 to $4.16 EPS, and FY2029 to $7.36 EPS, while maintaining a Buy rating and a $100 price target. IMCR analyst estimate update
• Positive Sentiment: HC Wainwright also nudged up near-term estimates for Q1 2027, Q2 2027, Q3 2027, and Q4 2027, signaling improving expectations for earnings momentum. IMCR analyst estimate update
• Positive Sentiment: Zacks Research upgraded Immunocore from “strong sell” to “strong-buy,” adding to the bullish sentiment around the shares. Zacks upgrade
• Neutral Sentiment: Immunocore remains a loss-making company on a full-year basis, with consensus estimates still calling for a loss this year, so investors will be watching whether the company can continue narrowing losses and converting analyst optimism into actual results. Valuation and Q1 results discussion

Immunocore Company Profile

Immunocore plc is a clinical?stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T?cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T?cell receptors against cancer) platform utilizes engineered, soluble T?cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease?associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma?associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.